2 November 2023 - Gedeon Richter together with Sumitomo today announce that the European Commission has granted approval of a type II variation application for Ryeqo (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. 

This decision followed a positive opinion from the CHMP’ of the EMA on 15 September 2023 and is applicable for all Member States in the European Union.

Read Gedeon Richter press release